What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity

Abstract

Primary leiomyosarcoma of bone (LMSoB) is extremely rare, comprising only p = 0.0015). Axial tumor localization was associated with worse event-free survival (EFS) probability (p p = 0.0082). A high proportion of our patients developed secondary metastases. Furthermore, the perioperative chemotherapy protocols applied to our patients were not associated with an improved EFS or OS. Therefore, the benefit of perioperative chemotherapy in LMSoB needs to be further investigated, and the choice of agents still needs to be clarified.

Keywords

• leiomyosarcoma of bone
• bone sarcoma
• systemic chemotherapy
• surgical treatment
• patient outcome
• rare primary malignant bone sarcoma (RPMBS)